Mark Douglas Smith

This profile gathers the share dealings of Mark Douglas Smith across 3 companies, led by Jazz Pharmaceuticals plc, Phreesia, Inc. and Teladoc Health, Inc. Between 14 May 2021 and 5 August 2026, the trades on record add up to 20 filings.

Market trades split into 1 purchase (€26k) and 3 sales (€152k). The net balance comes to €126k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 11 share grants and 5 option exercises.

The record was last updated on 7 August 2026 with a share grant in Jazz Pharmaceuticals plc. The clock since the last published purchase (19 August 2024) now reads 790 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.